Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,981 shares of the biotechnology company’s stock after selling 1,373 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Exelixis were worth $499,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Tri Ri Asset Management Corp acquired a new position in Exelixis during the third quarter worth $4,396,000. Blue Trust Inc. boosted its holdings in Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after buying an additional 8,208 shares during the last quarter. Range Financial Group LLC purchased a new stake in Exelixis during the 4th quarter worth approximately $994,000. FMR LLC raised its holdings in shares of Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after acquiring an additional 140,568 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Exelixis by 82.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after acquiring an additional 704,786 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of EXEL stock opened at $37.72 on Tuesday. The company has a 50-day moving average of $35.66 and a two-hundred day moving average of $33.00. The firm has a market cap of $10.56 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Activity

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently commented on EXEL shares. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday, February 13th. Royal Bank of Canada raised their price target on shares of Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. Wells Fargo & Company lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price on the stock. in a research note on Monday, February 24th. Finally, Morgan Stanley upgraded Exelixis from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $30.00 to $40.00 in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.